Recruiting Cancer Clinical Trials

ETOP Adeppt

A multicentre, single-arm phase II trial of adagrasib in patients with KRAS G12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status.
Description: This is a single arm trial assessing the effectiveness of adagrasib in patients with non-small cell lung cancer that have the KRAS G12C mutation. This trial includes those over 70 years or age or those that have a poor performance status
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

HARMONi-3 (SMT112-3003)

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Description: 1st Line Metastatic Squamous NSCLC
Study Phase: Phase 3
Principal Investigator: Dr Sinead Cuffe
Further information

Krystal-7

A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Description: This trial is recruiting patients with advanced lung cancer . The cancer must have a particular mutation called KRAS G12C. Patients will either receive a new drug called MRTX849 alone or in combination with pembrolizumab
Study Phase: Phase 2
Principal Investigator: Sinead Cuffe
Further information

MK-2870-023

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
Description: To compare pembrolizumab with or without maintenance MK-2870 with respect to Overall Survival (OS) Hypothesis (H1): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect to OS To compare pembrolizumab with or without maintenance MK-2870 with respect to PFS per RECIST 1.1 as assessed by BICR Hypothesis (H2): Pembrolizumab with maintenance MK-2870 is superior to pembrolizumab without maintenance MK-2870 with respect t
Study Phase: Phase 3
Principal Investigator: Dr. Sinead Cuffe
Further information